Platelet-activating factor (PAF) is not an essential component of the cascade leading to smooth muscle cell proliferation following vascular injury
Autor: | A.M. Mares, F. Dol, J.M. Herbert, M.C. Laplace |
---|---|
Rok vydání: | 1995 |
Předmět: |
Male
medicine.medical_specialty Intimal hyperplasia Endothelium Platelet Aggregation medicine.drug_class Immunology Muscle Smooth Vascular chemistry.chemical_compound Restenosis Internal medicine medicine.artery Medicine Animals Vascular Diseases Platelet Activating Factor Aorta Pharmacology Hyperplasia Platelet-activating factor business.industry Cell growth medicine.disease Receptor antagonist Thiazoles Endocrinology medicine.anatomical_structure chemistry Cardiology Endothelium Vascular Rabbits business Ex vivo Cell Division |
Zdroj: | Journal of lipid mediators and cell signalling. 12(1) |
ISSN: | 0929-7855 |
Popis: | In order to evaluate the relative importance platelet-activating factor (PAF) in the proliferative process leading to restenosis, the effect of SR 27417, a novel highly potent PAF receptor antagonist, on PAF-induced rabbit aortic smooth muscle cell (SMC) proliferation and intimal hyperplasia in rabbit carotid arteries subjected to air-drying endothelial injury was investigated. When added to low concentrations of foetal calf serum, PAF showed a dose-dependent mitogenic effect with regard to rabbit arterial SMC. SR 27417 inhibited PAF-induced SMC growth (IC50 = 2.4 +/- 0.4 nM) but remained without effect on the mitogenic effect of foetal calf serum. A 16 day treatment of SR 27417 (10 mg/kg per day, p.o.) abrogated PAF-induced platelet aggregation ex vivo but did not affect the development of intimal thickening, therefore showing that PAF is not an essential component of the cascade leading to restenosis following vascular injury. |
Databáze: | OpenAIRE |
Externí odkaz: |